ClinicalTrials.gg
CompletedNCT05810948Updated Dec 18, 2025

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

A Phase 2 interventional study of efgartigimod IV and Placebo in Lupus Nephritis, sponsored by argenx. Completed at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Enrollment
37th of 88
73 · median 51
Started
2023
with 8 others
Phase 2
19 of 96
8 open now
Registered
49th of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 37th largest by enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2023, is one of 19 in phase 2, and was the 49th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of efgartigimod IV in Chinese patients with active lupus nephritis (LN). The study comprises an approximate 4-week screening period, a 24-week treatment period, and an 8-week follow- up period.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • Nephritis
  • Lupus Nephritis
  • Kidney Disease
  • Urologic Disease
  • Glomerulonephritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years when signing the form (ICF)
  • Capable of providing signed informed consent, and complying with protocol requirements
  • Diagnosis of SLE according to the Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 classification criteria
  • Active, proliferative LN Class III or IV [excluding Class III (C), IV-S (C), and IV-G (C)], either with or without the presence of Class V using the 2003 International Society of Nephrology (ISN)/Renal Pathology Society (RPS) criteria, proven by kidney within 6 months before randomization and confirmed by the central biopsy reading group
  • Require LN induction therapy ( and MMF/MPA) based on investigator's clinical judgment. Induction therapy may begin before screening but should be initiated within 60 days before randomization
  • Agree to use consistent with local regulations. Full inclusion criteria can be found in the protocol

Exclusion criteria

Exclusion Criteria:

  • Active or chronic infection requiring treatment
  • Any evidence of central nervous system lupus (including but not limited to seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis)
  • Currently on renal dialysis or expected to require dialysis during study period
  • Previous kidney transplantation or planned transplantation during study period
  • History of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before randomization. The following cancers are not exclusionary: basal cell or squamous cell skin cancer; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histological finding of prostate cancer
  • Heart failure due to Systemic Lupus Erythematodes, or any other severe cardiovascular involvement with safety concerns according to investigator's judgment
  • Any other known disease that would interfere with an accurate assessment of clinical symptoms of SLE/LN or put the participant at undue risk
  • Previously failed treatment with MMF or any form of mycophenolate-based induction therapy, based on the investigator's opinion
  • Use of complementary therapies, including Traditional Chinese Medicine, herbs, or procedure (eg, acupuncture) that can potentially interfere with the efficacy and safety of participants as assessed by the investigator
  • SARS-CoV-2 antigen-based positive test at screening. The test is required regardless of whether the participant has been vaccinated
  • Known or to efgartigimod, any of the IMP, or SoC medication used in the study
  • In the opinion of the investigator, current or history of (ie, within 12 months of randomization) alcohol, drug, or medication abuse
  • Pregnant or lactating females and those who intend to become pregnant during study participation
  • Any conditions or circumstances that in the opinion of the investigator may make the participant unsuitable for the study

The full list of criteria can be found in the protocol.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    efgartigimod IV

    Patients receiving intravenous (IV) infusions of efgartigimod

    Biological: efgartigimod IV

  • Placebo comparator
    Placebo

    Patients receiving intravenous (IV) infusions of placebo

    Other: Placebo

Interventions

  • Biologicalefgartigimod IV

    Intravenous (IV) infusion of efgartigimod

  • OtherPlacebo

    Intravenous (IV) infusion of placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 24 in urine protein creatinine ratio (UPCR)

    Time frame: up to 24 weeks

Secondary outcomes

  1. Proportion of participants achieving complete renal response (CRR) at week 24

    Time frame: up to 24 weeks

  2. Time to complete renal response (CRR)

    Time frame: up to 32 weeks

  3. Proportion of participants achieving partial renal response at week 24

    Time frame: up to 24 weeks

  4. Time to partial renal response (PRR)

    Time frame: up to 24 weeks

  5. Change from baseline to week 24 in estimated glomerular filtration rate (eGFR)

    Time frame: up to 24 weeks

  6. Change from baseline to week 24 in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K score

    Time frame: up to 24 weeks

  7. Change from baseline to week 24 in the dosage of glucocorticoids

    Time frame: up to 24 weeks

  8. Treatment failure rate during treatment period

    Time frame: up to 24 weeks

  9. Proportion of participants achieving modified complete renal response (mCRR) at week 24

    Time frame: up to 24 weeks

  10. Efgartigimod serum concentration-time profile

    Time frame: up to 32 weeks

  11. Changes from baseline in levels of total IgG

    Time frame: up to 32 weeks

  12. Incidence of ADA against efgartigimod

    Time frame: up to 32 weeks

  13. Median changes in concentration from baseline over time in biomarkers (Anti-dsDNA, C3, C4 and CH50)

    (all have the same measuring units)

    Time frame: up to 32 weeks

  14. Change from baseline to week 24 in EuroQoL 5-Dimension 5-Level (EQ-5D-5L) score

    Time frame: Up to 24 weeks

07

Study locations

31 sites
  • Peking University Third Hospital
    Beijing, 100191, China
  • Peking University People's Hospital
    Beijing, China
  • Hunan Provincial People's Hospital
    Changsha, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Fujian Medical University Union Hospital
    Fujian, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, China
  • The First Affiliated Hospital,Sun Yat-sen University
    Guanzhou, China
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, China
  • First Affiliated Hospital of University of South China
    Hengyang, China
  • The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
    Huainan, China
  • Jieyang People's Hospital
    Jieyang, 522091, China
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University
    Jinan, China
  • Affiliated Hospital of Jining Medical University
    Jining, China
  • Liu Zhou Works Hospital
    Liuzhou, China
  • Jiangxi Provincial People's Hospital
    Nanchang, 330006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Province Hospital
    Nanjing, China
  • Zhongda Hospital Southeast University
    Nanjing, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, China
  • Huashan Hospital Fudan University
    Shanghai, China
  • ShengJing Hospital of China Medical University
    Shenyang, China
  • Shenzhen People's Hospital
    Shenzhen, China
  • The First Hospital of Hebei Medical University
    Shijia Zhuang, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, China
  • Renmin Hospital of Wuhan University
    Wuhan, China
  • Wuxi People's Hospital
    Wuxi, China
  • Shaanxi Provincial Hospital of Chinese Medicine
    Xi'an, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 310058, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jul 2025, 28 months.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Apr 13, 2023
StartActual
Feb 21, 2023
Primary completionActual
Jul 2, 2025
CompletionActual
Sep 1, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05810948
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Apr 13, 2023
Start date
Feb 21, 2023
Primary completion
Jul 2, 2025
Completion
Sep 1, 2025
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion